Enabling Cutting-Edge Technologies That Will Help Shape Our Future

​2123 Frontiers uses our research, experts, and gatherings to take a systems approach to “enable” current cutting-edge technologies in science, engineering, medicine and technology.

Defining a frontier or breakthrough is no easy feat, but at its core, we believe these are “significant” advancements with the potential to create a positive impact on humanity. Honestly, some of them will work, and many may not. Some will be quick; some will take decades. The most important thing is to have the aspiration to change the trajectory of societal impact.

We believe this magic happens at the intersection of science, medicine, business, and engineering, driven by leaders who have the boldness, resilience, and persistence to push the envelope on new frontiers and drive breakthroughs!! Our platform brings together driven entrepreneurs, innovators, pioneers, and visionaries, all with a common purpose — “enabling” breakthroughs as we collectively push society’s frontiers.

Our Frontiers

Healthcare & Life Sciences

The pace of medical innovation continues to accelerate with new ideas being pursued. Scientists are focused on several major areas of unmet need from rare diseases (Huntington’s disease, sickle cell anemia) to neurological conditions (Alzheimer's, Parkinson's, Epilepsy) to oncology (pancreatic cancer, lung cancer, colorectal cancer) and metabolic health (diabetes, obesity, hormonal conditions).

Scientists have been making significant progress on many new tools and foundational capabilities e.g. gene editing, pharmacogenomics, personalized medicine, predictive analysis, novel biomarkers, implantable/wearable devices, tissue cell engineering. These new diagnostics, devices, drugs, and software/AI will allow us to better tackle some of the most impactful diseases in medicine.

We want to enable innovators, scientists, physicians, investors and entrepreneurs to accelerate the pace of medical innovation for humanity.

High Tech

Solutions that improve data structure, data architecture models, and data related technologies such as generative AI, large language models, cloud-native data, real time data processing are foundational.

Advancement in computation such as hardware advancement (quantum computing, semiconductors), software, and algorithms (high performance computing, quantum algorithms) are enabling the processing of larger amounts of data.

Spatial computing, Augmented reality (AR), Virtual reality (VR) and mixed reality is considered the next big paradigm shift in computing, enabling human-computer interaction to take place in the real world, in and around natural bodies and physical environments.

Innovations in robotics such as soft robotics, autonomous systems, human-robot interactions, bio-inspired robotics and AI and robotics integration have wide-ranging applications in a variety of industries such as healthcare, manufacturing, education.

To enable the secure implementation of technology, advances in cybersecurity tools such as zero trust architecture, next generation cloud workforce protection, password-less authentication, blockchain, quantum computing as well as ethical and legal guidelines must be put into place.

All these innovations will contribute to transformation in every industry and bringing us closer to a reality once only imagined!

Company Spotlight: Vicero

Overview: Vicero is a Cambridge based, preclinical-stage biotech developing a transformational platform of multi-specific VHH "VINCOBODIES™”, designed to deliver best-in-class, highly differentiated therapies delivering high efficacy at very low doses and decreased toxicity. Vicero believes they will be successful in delivering immune-oncology (IO) and chemotherapy combinations, without the toxicity limitations associated with current standard of care therapies.

Key Scientific Highlights:

  • Best-in-Class multi-specific VINCOBODIES: Lead is a pentavalent PD-1/CTLA-4 bi-specific engineered for femtomolar potency.

  • Fc-Free Design: VICOBODIES designed without a Fc domain, which eliminates Fc mediated toxicity at the architectural level.

  • Combination with existing therapies: Approved PD-1/CTLA-4 combinations such as Opdivo + Yervoy define the efficacy ceiling and the toxicity floor, Vicero expects a step-change in tolerability at equal or greater efficacy, thereby broadening the patient pool.

  • Expandable Architecture: The mix-and-match VINCOBODY platform, is a checkpoint optimization tool with upside across 25+ targets and a current multi-$10B+ opportunity across CRC, NSCLC, HCC and beyond.

Leadership: Vikram Kansra, PhD (CEO), Alison Finger, MBA (COO), Han Myint, MD (CMO), Pallavi Tawde, PhD (CTO), Elena Chekhova (CBO) and Charles Shoemaker, PhD (Founding Scientific Innovator).

Financials: $4.5 - $5M raised to date. $30M Series A, with flexibility around structure (potential staging via $15M initial tranche + milestone-based expansion). $80M for full three tumor expansion.

Looking Ahead: The Path to Clinical Proof of Concept

Vicero has established a rigorous 24-month roadmap to achieve human clinical validation:

  • IND Readiness: VCR-036 is positioned to enter IND-enabling studies in less than 12 months.

  • Australia Pathway: Utilization of the CTN scheme for rapid First-in-Human dosing, capturing a 43.5% cash rebate to maximize capital efficiency.

  • Phase 1 Proof of Concept (POC): Targeted clinical validation in CRC, NSCLC, and HCC, with POC achievable with a few months of study start.

Login to Access Content

2123 Frontiers Salon

An engaging evening of conversation, connection, advise shared over some amazing updates from the Biotech featured on the 2123 Frontiers platform, Reverb Therapeutics, Neuropeutics Inc, Aveta Biomics Inc and Switchback Therapeutics.